| Page 111 | Kisaco Research

Review how decision intelligence is transforming the way organisations plan and execute complex projects. Apply decision intelligence to high-stakes environments such as clinical trials and learn how AI can dramatically reduce trial-planning timelines, optimise trial execution, and improve portfolio-level decision-making. Explore how leading enterprises are using Decision Intelligence platform to bring greater clarity, speed, and confidence to their most critical operational and strategic decisions.

Author:

Andrew Brookes

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.

 

... read more

Andrew Brookes

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.

 

This session explores how hybrid AI infrastructure is transforming drug discovery by integrating on-premises, private cloud, and public cloud resources for optimal data control, computational power, scalability, and security. Attendees will learn how pharmaceutical organizations use cutting-edge AI and machine learning tools for target identification and molecular design, while maintaining compliance with strict regulatory standards. The presentation will cover the architecture and core components of hybrid infrastructure, including high-performance computing, data management, MLOps, and compliance frameworks. Key benefits such as accelerated R&D, cost reduction, improved collaboration, and flexible scalability will be discussed, alongside real-world case studies. The session will also address challenges like data integration, interoperability, regulatory complexity, and AI interpretability, offering practical strategies to overcome these obstacles.

Author:

Alex Madama

Distinguished Technologist
Hewlett Packard Enterprise

Alex Madama is a Distinguished Technologist at Hewlett Packard Enterprise, specializing in strategic technology integration for life sciences organizations, including healthcare, pharmaceutical, biotech, and medical device companies. He leads initiatives combining high-performance computing, Hybrid Cloud, IoT, big data, and AI to advance drug discovery, pharmaceutical R&D, and biologics manufacturing, aiming to optimize patient outcomes and reduce costs. Before re-joining HPE, Alex served as Vice President of Product at UnitedHealth Group R&D, where he drove innovation in healthcare research and development. He holds a bachelor’s degree in life science and a Doctor of Osteopathic Medicine from New York Institute of Technology, with additional clinical training at Good Samaritan Hospital Medical Center, and lectures as an Adjunct Professor of Health Information Technology at Hofstra University. Previously, Alex founded Onyx CCS and held leadership roles at Nook.com, Barnes & Noble, AIG, Cravath Swaine & Moore, and as founder of seekPhysician.com.

... read more

Alex Madama

Distinguished Technologist
Hewlett Packard Enterprise

Alex Madama is a Distinguished Technologist at Hewlett Packard Enterprise, specializing in strategic technology integration for life sciences organizations, including healthcare, pharmaceutical, biotech, and medical device companies. He leads initiatives combining high-performance computing, Hybrid Cloud, IoT, big data, and AI to advance drug discovery, pharmaceutical R&D, and biologics manufacturing, aiming to optimize patient outcomes and reduce costs. Before re-joining HPE, Alex served as Vice President of Product at UnitedHealth Group R&D, where he drove innovation in healthcare research and development. He holds a bachelor’s degree in life science and a Doctor of Osteopathic Medicine from New York Institute of Technology, with additional clinical training at Good Samaritan Hospital Medical Center, and lectures as an Adjunct Professor of Health Information Technology at Hofstra University. Previously, Alex founded Onyx CCS and held leadership roles at Nook.com, Barnes & Noble, AIG, Cravath Swaine & Moore, and as founder of seekPhysician.com.

Advanced computing is a strategic imperative for pharmaceutical innovation. The industry is at a point where traditional computational methods are no longer sufficient to solve the increasingly complex problems in R&D and operations. Embracing technologies like quantum computing and HPC is critical for maintaining a competitive edge and driving breakthroughs.

A hybrid approach is essential for a complete solution. No single technology is the silver bullet. The most effective solutions come from using the right tools—be it classical, quantum, or quantum-inspired—and combining them into a single, powerful workflow to maximize efficiency and impact. This approach allows companies to apply the best technology to a wide range of problems across the business, not just in drug discovery.

Strategic partnerships are key to capability building. For a large enterprise like J&J, the path to adopting these advanced technologies is best navigated through collaboration. Working with a specialist like Strangeworks bridges the knowledge gap, provides access to powerful platforms, and helps overcome organizational hurdles. The ultimate goal of this collaborations like these is to be able to empower J&J's internal teams to become self-sufficient pioneers of innovation.

Author:

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.

... read more

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.

Author:

Selene Sass

Technology Product Manager
Johnson and Johnson

Selene is a technology product manager at Johnson & Johnson with nearly five years supporting the Advanced Computing and Analytics team. Her primary focus is to empower R&D scientists with emerging and innovative technologies in the advanced computing space, including the integration of quantum computing within J&J. Currently, she supports groups working in AI/ML and is exploring how quantum computing techniques can further enhance these capabilities. 

... read more

Selene Sass

Technology Product Manager
Johnson and Johnson

Selene is a technology product manager at Johnson & Johnson with nearly five years supporting the Advanced Computing and Analytics team. Her primary focus is to empower R&D scientists with emerging and innovative technologies in the advanced computing space, including the integration of quantum computing within J&J. Currently, she supports groups working in AI/ML and is exploring how quantum computing techniques can further enhance these capabilities. 

  • Learn how AI analyzes patent and R&D data to identify chemical trends, aiding in compound optimization.
  • Discover how integrating diverse data sources streamlines the optimization of drug candidates, enhancing decision-making.

Author:

Sam Winders

Account Director
Patsnap

Sam is the lead representative for the healthcare and life sciences team at Patsnap. One of the organization’s longest serving employees, Sam works closely with our leading customers and the Patsnap product development team to ensure that our customers’ needs our met and that Patsnap continues to rapidly expand the technical frontier within the evolving drug discovery space. 

... read more

Sam Winders

Account Director
Patsnap

Sam is the lead representative for the healthcare and life sciences team at Patsnap. One of the organization’s longest serving employees, Sam works closely with our leading customers and the Patsnap product development team to ensure that our customers’ needs our met and that Patsnap continues to rapidly expand the technical frontier within the evolving drug discovery space. 

Author:

Christina V. McDonough

Principal
Fish & Richardson P.C.

Christina McDonough helps clients with patent prosecution, portfolio management, reexamination, counseling, and due diligence for clients ranging from small start-ups to large companies and academic institutions. She co-leads the firm’s standard essential patent (SEP) practice. 

Christina has particular expertise in the areas of artificial intelligence, digital therapeutics, bioinformatics and medical systems (e.g., telehealth, medical registries, readmission reductions, modeling and predictive analysis of biological data, genetic codes, and immunotherapy response), computational fluid dynamics (e.g., simulation of acoustic and fluid flow properties), complex data processing (e.g., big data and complex events), and financial algorithms (e.g., predictive modeling and forecasting of real-time security trades).

... read more

Christina V. McDonough

Principal
Fish & Richardson P.C.

Christina McDonough helps clients with patent prosecution, portfolio management, reexamination, counseling, and due diligence for clients ranging from small start-ups to large companies and academic institutions. She co-leads the firm’s standard essential patent (SEP) practice. 

Christina has particular expertise in the areas of artificial intelligence, digital therapeutics, bioinformatics and medical systems (e.g., telehealth, medical registries, readmission reductions, modeling and predictive analysis of biological data, genetic codes, and immunotherapy response), computational fluid dynamics (e.g., simulation of acoustic and fluid flow properties), complex data processing (e.g., big data and complex events), and financial algorithms (e.g., predictive modeling and forecasting of real-time security trades).

Author:

Crystal Culhane Ph.D.

Principal
Fish & Richardson P.C.

Crystal Culhane, Ph.D., applies her extensive academic background in organic chemistry to help life sciences organization protect their products and innovations through U.S. and foreign patent prosecution, client counseling, due diligence, patentability and freedom to operate opinions, patent opinions, and post-grant proceedings.

Known as a responsive communicator with a strong depth of knowledge, Crystal works with clients ranging from universities to start-ups and growing companies to multinational organizations to prepare intellectual property strategies that suit their business goals.

In recent years, Crystal has worked with a number of pharmaceutical clients in high-impact patent prosecution. Her clients include a large pharmaceutical company for which she has helped develop and manage a portfolio of several hundred patent families and another which in 2021 received its first-ever FDA approval for a new drug that treats a rare liver disease.

Crystal earned her doctorate in chemistry at Johns Hopkins University, where her research focused on the design, synthesis, and evaluation of novel optical and radioactive small molecule prostate cancer imaging agents. She has significant experience in various scientific disciplines, including synthetic organic chemistry, radiochemistry, biology, radiobiology, and small animal imaging.

... read more

Crystal Culhane Ph.D.

Principal
Fish & Richardson P.C.

Crystal Culhane, Ph.D., applies her extensive academic background in organic chemistry to help life sciences organization protect their products and innovations through U.S. and foreign patent prosecution, client counseling, due diligence, patentability and freedom to operate opinions, patent opinions, and post-grant proceedings.

Known as a responsive communicator with a strong depth of knowledge, Crystal works with clients ranging from universities to start-ups and growing companies to multinational organizations to prepare intellectual property strategies that suit their business goals.

In recent years, Crystal has worked with a number of pharmaceutical clients in high-impact patent prosecution. Her clients include a large pharmaceutical company for which she has helped develop and manage a portfolio of several hundred patent families and another which in 2021 received its first-ever FDA approval for a new drug that treats a rare liver disease.

Crystal earned her doctorate in chemistry at Johns Hopkins University, where her research focused on the design, synthesis, and evaluation of novel optical and radioactive small molecule prostate cancer imaging agents. She has significant experience in various scientific disciplines, including synthetic organic chemistry, radiochemistry, biology, radiobiology, and small animal imaging.

Author:

Lana Gladstein

General Counsel
Seaport Therapeutics

Lana Gladstein currently works as a General Counsel for Seaport Therapeutics. She previously worked at APRINOIA Therapeutics as a Group General Counsel. Lana Gladstein attended Northeastern University School of Law.

... read more

Lana Gladstein

General Counsel
Seaport Therapeutics

Lana Gladstein currently works as a General Counsel for Seaport Therapeutics. She previously worked at APRINOIA Therapeutics as a Group General Counsel. Lana Gladstein attended Northeastern University School of Law.

 

Jeremy Hill

VP, Payer Solutions
Optum

Jeremy Hill

VP, Payer Solutions
Optum

Jeremy Hill

VP, Payer Solutions
Optum

Join us for a demo showcasing the power of Google Cloud TPU by walking through the complete lifecycle of a model, from post-training to inference at massive scale.

We’ll show you how to post-train a model using new RL capabilities in MaxText and Tunix, then take that same model and serve it on TPU seamlessly with the new JAX backend in vLLM.

Learn about how to rightsize a workload for TPU for both training and inference, optimizing for performance-per-dollar from beginning to end.

Author:

Brittany Rockwell

Product Manager
Google Cloud

Brittany Rockwell is a Product Manager for AI Inference at Google Cloud, where she leads the development of the TPU backend in vLLM, the most popular OSS library for language model inference. She currently lives in Seattle, WA.

... read more

Brittany Rockwell

Product Manager
Google Cloud

Brittany Rockwell is a Product Manager for AI Inference at Google Cloud, where she leads the development of the TPU backend in vLLM, the most popular OSS library for language model inference. She currently lives in Seattle, WA.

Author:

Kyle Meggs

Product Manager
Google Cloud

Kyle Meggs is a Product Manager for JAX on Google Cloud. He enjoys helping customers train LLMs with MaxText and  diffusion models with MaxDiffusion on the latest TPUs and GPUs.

... read more

Kyle Meggs

Product Manager
Google Cloud

Kyle Meggs is a Product Manager for JAX on Google Cloud. He enjoys helping customers train LLMs with MaxText and  diffusion models with MaxDiffusion on the latest TPUs and GPUs.

The transition to direct liquid cooling introduces challenges from unavoidable leaks, risking catastrophic hardware failure, costly downtime, and data loss– until now. actnano is AI's Missing Layer: the last line of defense for these mission critical assets. Our next-generation coating is the first truly proactive protection strategy for data infrastructure. Witness our live demonstration where an actnano-coated graphics card operates flawlessly while subjected to a simulated leak of conductive coolant. This technology engineers catastrophic failures into simple maintenance events, making hardware truly liquid-proof. See firsthand how to de-risk investments and unlock a new era of resilience, sustainability, and uptime.

Author:

Ken Aduddell

Senior Director
actnano

Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era. Previously at Rockwell Automation, Ken now leads actnano's initiative to protect critical hardware with this breakthrough coating technology.

... read more

Ken Aduddell

Senior Director
actnano

Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era. Previously at Rockwell Automation, Ken now leads actnano's initiative to protect critical hardware with this breakthrough coating technology.